Assessing Hepatoxicants based on High-throughput Quantitative SILAC Proteomics and Causal Biological Networks

Ahmed Enayetallah¹, Sashi Nadanaciva², Paul Ajuh³, Cristina Vazquez Martin³, Amy Wheat³, Angus Lamond³, Daniel Ziemek⁴ and Karen L Leach^2,5*

¹Translational Medicine, Biogen Idec, Cambridge, Massachusetts, USA

²Compound Safety Prediction, Pfizer Global Research and Development, Pfizer, Inc, Groton, Connecticut, USA

³Dundee Cell Products, Dundee, SCOTLAND

⁴Computational Sciences Center of Emphasis, Pfizer Global Research and Development, Pfizer, Inc, Berlin, Germany

⁵Pfizer Global Research and Development, Centers for Therapeutic Innovation, Boston, Massachusetts, USA

^*Corresponding Author: Karen L Leach, Safety Prediction, Pfizer Global Research and Development, Pfizer, Inc, Groton, Connecticut, USA, Tel: +1 860-441-4100